When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk is planning to open an artificial ... In September, for example, the company signed an agreement with US start-up Valo Health to apply its AI-powered drug discovery engine to find ...

Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn. Artificial intelligence (AI) has long promised ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk (NVO) was slammed by a U.K. trade group for violating voluntary codes and discrediting the pharmaceutical industry over a failure ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...

Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

This page features the latest news about the Novo Nordisk B stock. Deutsche Bank cuts Novo Nordisk stock target, keeps Buy rating on Q3 results On Thursday, an analyst from Deutsche Bank (ETR ...

Novo Nordisk's (CO:NOVOb) top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a... Investing.com – Denmark stocks were lower after ...